PRO-LAD

PRO-LAD
Systematic (IUPAC) name

(8β)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide
Clinical data
Routes of administration	Oral
Legal status	Controlled in the United States via the Federal Analog Act but only if it is intended for human consumption.
Pharmacokinetic data
Metabolism	hepatic
Excretion	renal
Identifiers
CAS Number	65527-63-1^Y
PubChem	CID 44457803
ChemSpider	21106361^Y
ChEMBL	CHEMBL22258^Y
Synonyms	PRO-LAD, 6-propyl- 6-nor- Lysergic acid diethylamide, (6aR,9R)- N,N- diethyl- 7-propyl- 4,6,6a,7,8,9- hexahydroindolo- [4,3-fg] quinoline- 9- carboxamide
Chemical data
Formula	C₂₂H₂₉N₃O
Molar mass	351.50 g/mol
SMILES CCN(CC)C(=O)[C@@H]2/C=C1/c3cccc4ncc(C[C@H]1N(C2)CCC)c34
InChI InChI=1S/C22H29N3O/c1-4-10-25-14-16(22(26)24(5-2)6-3)11-18-17-8-7-9-19-21(17)15(13-23-19)12-20(18)25/h7-9,11,13,16,20,23H,4-6,10,12,14H2,1-3H3/t16-,20-/m1/s1^Y Key:HZKYLVLOBYNKKM-OXQOHEQNSA-N^Y
(verify)

PRO-LAD is an analogue of LSD. It is described by Alexander Shulgin in the book TiHKAL. PRO-LAD is a psychedelic drug similar to LSD, and is around as potent as LSD itself with an active dose reported at between 100 and 200 micrograms.^[1]

Legal Status

On June 10th 2014 the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that PRO-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use.^[2] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.

PRO-LAD is illegal in Switzerland as of December 2015.^[3]

Literature

Andrew J. Hoffman, David E. Nichols: Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. In: Journal of Medicinal Chemistry. 28, 1985, p. 1252–1255, doi:10.1021/jm00147a022.
T. Niwaguchi, Y. Nakahara, H. Ishii: Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. In: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. Vol. 96, No. 5, May 1976, p. 673–678, PMID 987200.
Robert C. Pfaff, Xuemei Huang, Danuta Marona-Lewicka, Robert Oberlender and David E. Nichols: Lysergamides Revisited. In: NIDA Research Monograph 146: Hallucinogens: An Update. p. 52, 1994, United States Department of Health and Human Services.

References

↑ Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry 28 (9): 1252–5. doi:10.1021/jm00147a022. PMID 4032428.
↑ ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014.
↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien". Der Bundesrat.

External links

Drugs mentioned in TiHKAL

Hallucinogens

Psychedelics
5-HT_2AR agonists

Lysergamides	1P-ETH-LAD 1P-LSD AL-LAD ALD-52 BU-LAD IP-LAD Diallyllysergamide Dimethyllysergamide Ergometrine ETH-LAD LAE-32 LPD-824 LSA LSD LSD-Pip LSH LSM-775 2-Butyllysergamide LSZ 3-Pentyllysergamide Methylergometrine Methylisopropyllysergamide Methysergide MLD-41 PARGY-LAD PRO-LAD

Phenethylamines	2-Bromomescaline 2-Methyl-MDA 2C-B 2C-B-AN 2C-B-DragonFLY 2C-B-BUTTERFLY 2C-B-FLY 2CBCB-NBOMe 2CB-Ind βk-2C-B 2C-C 2C-D 2C-E 2C-EF 2C-F 2C-G 2C-I βk-2C-I 2C-iP 2C-N 2C-O 2C-O-4 2C-P 2C-T 2C-T-2 2C-T-3 2C-T-4 2C-T-7 2C-T-8 2C-T-13 2C-T-15 2C-T-16 2C-T-17 2C-T-19 2C-T-21 2C-T-21.5 2C-T-22 2C-T-27 2C-T-28 2C-TFM 2C-YN 2CD-5EtO 25B-NBF 25C-NBF 25I-NBF 25B-NBOH 25C-NBOH 25CN-NBOH 25I-NBOH 25B-NBMD 25C-NBMD 25I-NBMD 25B-NBOMe 25C-NBOMe 25CN-NBOMe 25D-NBOMe 25E-NBOMe 25F-NBOMe 25G-NBOMe 25I-NBOMe 25N-NBOMe 25P-NBOMe 25TFM-NBOMe 3C-AL 3C-DFE 3C-E 3C-P 4C-B 4C-D 5-APB 5-EAPB 5-MAPB 5-APDB 5-MAPB 5-APDI 5-Methyl-MDA 6-APB 6-EAPB 6-MAPB 6-APDB 6-MAPDB 6-Methyl-MDA Aleph Bromo-DragonFLY Difluoroescaline Difluoromescaline DESOXY DMBMPP DMMDA DMMDA-2 DOB DOB-FLY DOC DOEF DOET DOF DOI DOiPR DOM DON DOPR DOTFM BOB BOD Escaline Fenfluramine Fluoroproscaline Ganesha HOT-2 HOT-7 HOT-17 Isoproscaline Jimscaline Lophophine Macromerine MDA MDEA MDMA Mescaline Mescaline-NBOMe Methallylescaline MMA MMDA MMDA-2 MMDA-3a MMDMA Proscaline TCB-2 TFMFly Trifluoroescaline Trifluoromescaline TMA

Piperazines	pFPP TMFPP mCPP

Tryptamines	1-Me-5-MeO-DiPT 2,N,N-TMT 4,5-DHP-α-MT 4,5-DHP-DMT 4-AcO-DALT 4-AcO-DET 4-AcO-DiPT 4-AcO-DMT 4-AcO-DPT 4-AcO-MiPT 4-HO-5-MeO-DMT 4-HO-DBT 4-HO-DPT 4-HO-MET 4-HO-MPMI 4-HO-MPT 4,N,N-TMT 4-Propionyloxy-DMT 5,6-diBr-DMT 5-AcO-DMT 5-Bromo-DMT 5-Me-MIPT 5-MeO-2,N,N-TMT 5-MeO-4,N,N-TMT 5-MeO-α,N,N-TMT 5-MeO-α-ET 5-MeO-α-MT 5-MeO-DALT 5-MeO-DET 5-MeO-DiPT 5-MeO-DMT 5-MeO-DPT 5-MeO-EiPT 5-MeO-MALT 5-MeO-MET 5-MeO-MiPT 5-MeO-MPMI 5-N,N-TMT 7,N,N-TMT α-ET α-MT α,N,N-TMT Aeruginascin Baeocystin Bufotenin DALT DBT DCPT DET DIPT DMT DPT EiPT Ethocin Ethocybin Ibogaine Iprocin MET Miprocin MiPT Norbaeocystin Noribogaine PiPT Psilocin Psilocybin Voacangine

Benzofurans	5-MeO-DiBF Dimemebfe

Others	AL-38022A ALPHA Efavirenz Lorcaserin M-ALPHA RH-34

Dissociatives
NMDAR antagonists

Arylcyclohexylamines	2-Fluorodeschloroketamine 3-HO-PCP 3-MeO-PCE 3-MeO-PCMo 3-MeO-PCP 4-MeO-PCP Arketamine Deschloroketamine Dieticyclidine Esketamine Ethketamine Eticyclidine Gacyclidine Ketamine Methoxetamine Methoxmetamine Methoxyketamine Norketamine PCPr Phencyclidine Rolicyclidine Tenocyclidine Tiletamine

Morphinans	Dextrallorphan Dextromethorphan Dextrorphan Racemethorphan Racemorphan

Diarylethylamines	Diphenidine Ephenidine Fluorolintane Methoxphenidine

Others	2-MDP 8A-PDHQ Aptiganel Budipine Delucemine Dexoxadrol Dizocilpine Etoxadrol Ibogaine Midafotel NEFA Neramexane Nitrous oxide Noribogaine Perzinfotel Remacemide Selfotel Xenon

Deliriants
mAChR antagonists

Miscellaneous

Cannabinoids
CB₁R agonists

Phytocannabinoids	Cannabinol THC (Dronabinol) THCV

Synthetic	4-HTMPIPO 5F-AB-FUPPYCA 5F-AB-PINACA 5F-ADB 5F-ADB-PINACA 5F-ADBICA 5F-AMB 5F-APINACA 5F-CUMYL-PINACA 5F-NNE1 5F-PB-22 5F-SDB-006 A-796,260 A-836,339 AB-001 AB-005 AB-CHFUPYCA AB-CHMINACA AB-FUBINACA AB-PINACA ADAMANTYL-THPINACA ADB-CHMINACA ADB-FUBINACA ADB-PINACA ADBICA ADSB-FUB-187 AM-630 AM-679 AM-694 AM-1220 AM-1221 AM-1235 AM-1241 AM-1248 AM-2201 AM-2232 AM-2233 AMB-FUBINACA APICA APINACA APP-FUBINACA CB-13 CP 47,497 CP 55,244 CP 55,940 CUMYL-PICA CUMYL-PINACA CUMYL-THPINACA DMHP EAM-2201 FAB-144 FDU-PB-22 FUB-144 FUB-APINACA FUB-JWH-018 FUB-PB-22 FUBIMINA HU-210 HU-308 JWH-007 JWH-015 JWH-018 JWH-019 JWH-030 JWH-073 JWH-081 JWH-098 JWH-116 JWH-122 JWH-149 JWH-167 JWH-182 JWH-193 JWH-198 JWH-200 JWH-203 JWH-210 JWH-250 JWH-251 JWH-398 JWH-424 JTE 7-31 JTE-907 Levonantradol MDMB-CHMICA MDMB-CHMINACA MDMB-FUBINACA MEPIRAPIM MAM-2201 MDA-19 MN-18 MN-25 NESS-0327 NESS-040C5 Nabilone Nabitan NM-2201 NNE1 Org 28611 Parahexyl PTI-1 PTI-2 PX-1 PX-2 PX-3 QUCHIC QUPIC RCS-4 RCS-8 SDB-005 SDB-006 STS-135 THC-O-acetate THC-O-phosphate THJ-018 THJ-2201 UR-144 WIN 55,212-2 XLR-11

D₂R agonists

Apomorphine
Aporphine
Bromocriptine
Cabergoline
Lisuride
Memantine
Nuciferine
Pergolide
Piribedil
Pramipexole
Ropinirole
Rotigotine
Also indirect D₂ agonists, such as dopamine reuptake inhibitors (cocaine, methylphenidate), releasing agents (amphetamine, methamphetamine), and precursors (levodopa).

GABA_AR enhancers

Inhalants
Mixed MOA

κOR agonists

Others

This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.

PRO-LAD

Legal Status

Literature

See also

References

External links